Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

NEOVACS ANNOUNCES THAT ITS PARTNER BIOSENSE GLOBAL HAS EXERCISED ITS OPTION TO ACQUIRE THE EXCLUSIVE LICENCE FOR IFNalpha KINOID TO TREAT LUPUS IN CHINA

NEOVACS
Posted on: 11 Sep 18

PRESS RELEASE · PRESS RELEASE · PRESS RELEASE

 NEOVACS ANNOUNCES THAT ITS PARTNER BIOSENSE GLOBAL HAS EXERCISED ITS OPTION TO ACQUIRE THE EXCLUSIVE LICENCE FOR IFNalpha KINOID TO TREAT LUPUS IN CHINA

Paris and Boston, 11 September 2018 - 07H00am CEST- Neovacs (Euronext Growth Paris ALNEV), leader in active immunotherapy for the treatment of auto-immune diseases, today announces that its partner Biosense Global has exercised its option as stipulated in the license agreement signed on February 2017 for a global value of up to 65 million euros. This agreement covers the development and commercialization in China of the therapeutic vaccine IFNalpha Kinoid for the indication Lupus [1] .

The decision by Biosense Global to exercise their option follows the results of the Phase IIb trial achieved by Neovacs with its IFNalpha  Kinoid in Lupus, which allows proceeding with the clinical development into phase III [2] .

Biosense Global acquires exclusive rights to develop and commercialize IFNalpha Kinoid for the treatment of Lupus in China and confirms their support and financial contribution to the Chinese part of a global Phase III program, when it starts within a global licensing agreement.

« The Phase IIb results have shown the relevance of Neovacs' unique technology of active immunotherapy in humans. The efficacy demonstrated motivates us to push ahead with our cooperation. Within trials conducted in lupus, LLDAS measures the patient disease activity state with the reduction of steroid use as one of the key components. This is emerging as a clinically meaningful outcome measure and is gaining increased support as a study endpoint from opinion leaders and clinicians in China and globally," explains Andy Li, PhD, CEO of Biosense Global, by adding : "Achieving statistically significance with this endpoint is a very important milestone for the project. We look forward to working with Neovacs and its other partners to further study the drug in the next stage of clinical development."

« China is the second largest pharmaceutical market in the world, where about 1 million people are suffering from this disease [3] . The pursuit of our cooperation with Biosense Global is a very positive development, and confirms the worldwide therapeutic potential of our lead product IFN Kinoid ," concludes Miguel Sieler, CEO of Neovacs.

According to the terms of the agreement Neovacs will receive a milestone payment following the exercising of the option. The company continues to pursue its discussions with other potential partners for a global licensing agreement.

About Biosense Global LLC
BioSense is an emerging biotech company established to address the business needs of the global biopharmaceutical market with a focus on China, Europe, and the U.S. The company is based in New Jersey (US) and Suzhou (China). The organization's mission is to bridge the gap between undercapitalized biopharmaceutical projects, companies, and investors to add value to its stakeholders and address significant unmet medical needs. BioSense's expert team of international biopharma executives and seasoned investors has extensive experience in developing, registering and commercializing some of the most successful products in key markets, including, US, Europe and China, plus the business management and cross-cultural knowledge while navigating entry into new markets and access to additional resources and funds.
http://www.biosensegloballlc.com/about/

About Neovacs
Listed on Euronext Growth since 2010, Neovacs is today a leading biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company's proprietary technology for inducing a polyclonal immune response (covered by four patent families that potentially run until 2032) Neovacs is focusing its clinical development efforts on IFNalpha Kinoid, an immunotherapy being developed for the indication of lupus, dermatomyositis and also in preclinical trial for Type 1 diabetes. Neovacs is also conducting preclinical development works on other therapeutic vaccines in the fields of auto-immune diseases, oncology and allergies. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases. www.neovacs.fr

Contact

NEOVACS - Corporate Communication & Investor Relations
Charlène Masson
+33 1 53 10 93 00
cmasson@neovacs.com


[1] Cf. Press Release published February 21, 2017- https://bit.ly/2LDSG98

[2] Cf. Press Release published July 3 , 2018 - https://bit.ly/2MLYa2D

[3] https://www.ncbi.nlm.nih.gov/pubmed/21148605

Press release


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: NEOVACS via GlobeNewswire
HUG#2215326
GlobeNewswire
globenewswire.com

Last updated on: 12/09/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.